Sanwa Kagaku Kenkyusho Co. Ltd. has synthesized imidazole derivatives acting as α1A-adrenoceptor agonists reported to be useful for the treatment of orthostatic hypotension and urinary incontinence.
Appicine Therapeutics (HK) Ltd. has disclosed proteolysis targeting chimera (PROTAC) compounds comprising a E3 ubiquitin ligase-binding moiety coupled to a Bcl-2-like protein 1 (Bcl-xL; Bcl-X; BCL2L1)-targeting moiety through a linker. They are reported to be useful for the treatment of cancer.
Researchers from Gempharmatech Co. Ltd. presented a new humanized mouse model for preclinical research into the functionality and therapeutic potential of IL-12.
Bioatla Inc. has received FDA clearance of its IND application for BA-3361, a conditionally active biologic (CAB)-Nectin-4 antibody-drug conjugate (ADC) for the treatment of multiple tumor types.
Researchers from ADC Therapeutics SA presented the discovery and preclinical evaluation of a novel camptothecin-based Claudin-6-specific antibody-drug conjugate (ADC), GB01-VA-PL2202.
Lantern Pharma Inc. has entered into a strategic artificial intelligence (AI)-driven collaboration with Oregon Therapeutics SAS to optimize the development of Oregon’s first-in-class protein disulfide isomerase (PDI) inhibitor drug candidate XCE-853 in novel and targeted cancer indications.
MicroRNAs (miRNAs) are small noncoding RNAs that play important roles in immune response regulation in autoimmune disease such as autoimmune hepatitis. Researchers investigated whether Δ8-tetrahydrocannabinol (THC), which is present in marijuana, could prevent the development of autoimmune hepatitis in treated mice by altering miRNA expression.
Eisbach Bio GmbH has announced FDA clearance of its IND application for EIS-12656, a first-in-class orally bioavailable and blood-brain barrier-penetrant allosteric inhibitor of ALC1 (CHD1L), a key molecular machine in DNA repair. Enrollment will open in the second quarter in a phase I/II trial in patients with genetically defined advanced solid tumors, including patients progressing under PARP inhibitor treatment.
Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, in part due to the immunosuppression surrounding the tumor mediated by regulatory T cells (Tregs), thus preventing effective responses to immune therapy.
RSS
